Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10523536 | PMC |
| http://dx.doi.org/10.1017/ash.2023.436 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Mike Edmond on the value of change, learning, and not letting others set the agenda.
Antimicrob Steward Healthc Epidemiol
August 2023
Chief Medical Officer, West Virginia University Health System, Morgantown, WV, USA.
Disparities in Vision Health and Eye Care.
Ophthalmology
October 2022
UCLA Stein and Doheny Eye Institutes, David Geffen School of Medicine, University of California, Los Angeles, California; Department of Epidemiology, Fielding School of Public Health, University of California Los Angeles, Los Angeles, California.
Significant disparities in vision health and eye care exist. To achieve health equity, we must understand the root causes and drivers of health disparities and inequities, including social determinants of health and systemic racism.
View Article and Find Full Text PDFValue of Clinical Signs in Identifying Patients with Scans without Evidence of Dopaminergic Deficit (SWEDD).
J Parkinsons Dis
September 2021
Department of Neurology, Amsterdam University Medical Centers, University of Amsterdam, Meibergdreef 9, Amsterdam, The Netherlands.
Background: In clinical trials that recruited patients with early Parkinson's disease (PD), 4-15% of the participants with a clinical diagnosis of PD had normal dopamine transporter single photon emission computed tomography (DAT SPECT) scans, also called "scans without evidence of dopaminergic deficit" (SWEDD).
Objective: To investigate in patients with a clinical diagnosis of PD, if specific clinical features are useful to distinguish patients with nigrostriatal degeneration from those that have no nigrostriatal degeneration.
Methods: We performed a diagnostic test accuracy study.
Lewy Body Dementia Association's Research Centers of Excellence Program: Inaugural Meeting Proceedings.
Alzheimers Res Ther
March 2019
Mayo Clinic campus, 200 1st Street SW, Rochester, MN, 55905, USA.
The first Lewy Body Dementia Association (LBDA) Research Centers of Excellence (RCOE) Investigator's meeting was held on December 14, 2017, in New Orleans. The program was established to increase patient access to clinical experts on Lewy body dementia (LBD), which includes dementia with Lewy bodies (DLB) and Parkinson's disease dementia (PDD), and to create a clinical trials-ready network. Four working groups (WG) were created to pursue the LBDA RCOE aims: (1) increase access to high-quality clinical care, (2) increase access to support for people living with LBD and their caregivers, (3) increase knowledge of LBD among medical and allied (or other) professionals, and (4) create infrastructure for a clinical trials-ready network as well as resources to advance the study of new therapeutics.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!